An innovative drug that promises to help deaf children regain their hearing capabilities has been approved in the United States, offering new hope to affected families. This groundbreaking development is particularly significant as the treatment will be available at no cost to eligible families across the nation.

The Food and Drug Administration (FDA) has granted approval for Otarmeni, a gene therapy designed to treat a rare genetic form of hearing loss. This condition, which impacts infants from birth, typically renders them completely deaf or capable of hearing only very loud sounds. The approval of Otarmeni represents a significant advancement in the field of auditory treatment.

Pharmaceutical company Regeneron has committed to providing this once-in-a-lifetime treatment for free to families who qualify. However, it’s important to note that medical expenses related to the administration of the treatment may still incur charges.

President Donald Trump highlighted this approval, emphasizing its availability through his TrumpRx pricing initiative. As part of a broader agreement with Regeneron, the medication will be offered at significantly discounted rates to ensure accessibility.

President Trump remarked, “I’m thrilled to announce that one of the most respected pharmaceutical companies globally, Regeneron, has agreed to provide their prescription medications at heavily discounted, most favored nation prices.”

The specific condition targeted by Otarmeni, known as OTOF-related hearing loss, affects approximately 50 newborns in the United States annually. This breakthrough offers a beacon of hope for families facing the challenges of this rare condition.

It is caused by a mutation in the OTOF gene, which leads to a faulty protein being made that prevents sound signals being passed from the ear to the brain.

In clinical trials involving 20 children with the mutation, 16 showed significant improvements in hearing after receiving the therapy.

Pictured above is Sierra Smith and her two-and-a-half-year-old Travis who was treated for the genetic condition using the breakthrough therapy

Five of the children recovered hearing so acute they were able to hear a whisper, reports said.

Experts have hailed the treatment as ‘life-changing’ for families, while Regeneron’s vice president said it marked the beginning of a ‘new era’ of hearing loss treatments.

Sierra Smith, whose two-and-a-half-year-old son Travis was treated with the gene therapy, said it had opened up a ‘different world’ to her family.

She said: ‘Watching him be able to interact with other children and even him knowing his name now and turning when I say his name is the craziest thing.

‘I can tell him how much I love him – it’s such a different world.’

Before the treatment was approved, the main option for children with the condition was cochlear implants, which can restore the ability to hear speech and music but may not detect softer sounds.

Unlike the gene therapy, implants do not provide natural round-the-clock hearing and require batteries to function.

The OTOF gene codes for otoferlin, a crucial protein in the inner ear’s hair cells that helps transmit sound signals to the brain.

In affected children, a mutated version of the protein leaves patients unable to hear anything or only very loud sounds.

In the new treatment, doctors use a modified virus to deliver a healthy copy of the OTOF gene into cells in the inner ear, helping restore hearing.

The virus is infused into the cochlea – the bony cavity within the inner ear – during surgery similar to that used for cochlear implants. These implants can be fitted from around nine months old.

In the clinical trial, side effects included ear infection or inflammation, vomiting, nausea and dizziness.

FDA Commissioner Dr Marty Makary said: ‘Today’s approval is a significant milestone in the treatment of genetic hearing loss.

‘Through the national priority voucher pilot program, the agency is accelerating therapies for rare diseases with unmet medical needs while proving we can successfully review even the most complex submissions… in significantly shortened timeframes.’

The treatment was approved via the national priority voucher program, designed to speed up reviews of breakthrough medicines from the usual 10 to 12 months to as little as one to two months.

More than 50 million Americans suffer from hearing loss, estimates suggest, making it the third most common chronic condition in the country.